- Report
- June 2025
- 93 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 89 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 196 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 214 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 453 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 377 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 382 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 172 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 467 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 282 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 62 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- August 2024
- 148 Pages
Global
From €2693EUR$2,999USD£2,293GBP
- Report
- April 2025
- 250 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Clinical Trials
- April 2025
- 150 Pages
Global
From €2245EUR$2,500USD£1,912GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1122EUR$1,250USD£956GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Report
- October 2024
- 198 Pages
Global
From €2245EUR$2,500USD£1,912GBP
- Report
- May 2025
- 119 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- December 2024
- 155 Pages
Global
From €3547EUR$3,950USD£3,020GBP

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more